Debt to Equity
since 2018
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Moderna Inc., debt to equity, long-term trends, calculation
| Debt to equity | = | Financing lease liabilities1 | ÷ | Stockholders’ equity1 | |
|---|---|---|---|---|---|
| Dec 31, 2023 | = | ÷ | |||
| Dec 31, 2022 | = | ÷ | |||
| Dec 31, 2021 | = | ÷ | |||
| Dec 31, 2020 | = | ÷ | |||
| Dec 31, 2019 | = | ÷ | |||
| Dec 31, 2018 | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
- Financing Lease Liabilities
- The financing lease liabilities show a significant upward trend from 2018 to 2022, starting at 43 million USD in 2018 and reaching a peak of 1,073 million USD in 2022. This represents a substantial increase, particularly between 2020 and 2021, where the amount jumped from 134 million USD to 764 million USD. However, in 2023, there is a notable decrease to 575 million USD, indicating a reduction in lease liabilities that year.
- Stockholders’ Equity
- Stockholders’ equity exhibits considerable growth over the period, beginning at 1,530 million USD in 2018 and escalating to 19,123 million USD in 2022. The most pronounced increase occurs between 2020 and 2021, where equity surged from 2,561 million USD to 14,145 million USD. Despite this strong growth trend, a decline is observed in 2023, with equity decreasing to 13,854 million USD.
- Debt to Equity Ratio
- The debt to equity ratio remains relatively stable throughout the period, fluctuating slightly between 0.03 and 0.06. It starts at 0.03 in 2018, holds steady through 2019, and then gently increases to 0.06 by 2022. In 2023, the ratio decreases to 0.04, signifying a modest improvement in the company's leverage position relative to its equity base.
- Summary of Financial Trends
- The data reflects significant growth in both financing lease liabilities and stockholders’ equity over the six-year period, highlighting increased financing activities and stronger equity positions until 2022. The peak in liabilities and equity in 2022 is followed by a reduction in 2023, suggesting possible deleveraging or asset revaluation. The relatively stable debt to equity ratio indicates balanced financial management despite the fluctuations in absolute values of liabilities and equity.
Comparison to Competitors
Moderna Inc., debt to equity, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | |||||||||||||
| Dec 31, 2022 | |||||||||||||
| Dec 31, 2021 | |||||||||||||
| Dec 31, 2020 | |||||||||||||
| Dec 31, 2019 | |||||||||||||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., debt to equity, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., debt to equity, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).